Impaired Response to Polysaccharide Vaccine in Selective IgE Deficiency
Purpose Immunoglobulin E deficiency (IgED) (defined as IgE
Gespeichert in:
| Veröffentlicht in: | Journal of clinical immunology 2023-08, Vol.43 (6), p.1448-1454 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1454 |
|---|---|
| container_issue | 6 |
| container_start_page | 1448 |
| container_title | Journal of clinical immunology |
| container_volume | 43 |
| creator | Noonan, Emily Straesser, Matthew D. Makin, Thomas Williams, Abigail Al-Hazaymeh, Amani Routes, John M. Verbsky, James Borish, Larry Lawrence, Monica G. |
| description | Purpose
Immunoglobulin E deficiency (IgED) (defined as IgE |
| doi_str_mv | 10.1007/s10875-023-01501-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2813556912</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3153158524</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-7c67856acd2cb77e39599acf05db51a156a4edaf68e9f6bc2acf5455efdb72f03</originalsourceid><addsrcrecordid>eNqFkVtLwzAYhoMobk7_gBdS8Mabag5Nk1zKnHMwUDzdhjT9OjO6diab0H9vdFPBC4VAAu_zvSF5EDom-JxgLC4CwVLwFFOWYsIxSbsd1CdcsJRyRXdRH1NBUkUy2kMHIcwxxiynfB_1mCC5Urnso_FksTTOQ5ncQ1i2TYBk1SZ3bd0FY-2L8a6E5DkeXQOJa5IHqMGu3Bskk9kouYLKWQeN7Q7RXmXqAEfbfYCerkePw5t0ejueDC-nqc2wXKXC5kLy3NiS2kIIYIorZWyFeVlwYkiMMihNlUtQVV5YGjOecQ5VWQhaYTZAZ5vepW9f1xBWeuGChbo2DbTroBnhcUlOs39RKgnjPFeERvT0Fzpv176JD4kUk1Jk8RcjRTeU9W0IHiq99G5hfKcJ1h9G9MaIjkb0pxHdxaGTbfW6WED5PfKlIAJsA4QYNTPwP3f_UfsO9QGWDw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2838874914</pqid></control><display><type>article</type><title>Impaired Response to Polysaccharide Vaccine in Selective IgE Deficiency</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Noonan, Emily ; Straesser, Matthew D. ; Makin, Thomas ; Williams, Abigail ; Al-Hazaymeh, Amani ; Routes, John M. ; Verbsky, James ; Borish, Larry ; Lawrence, Monica G.</creator><creatorcontrib>Noonan, Emily ; Straesser, Matthew D. ; Makin, Thomas ; Williams, Abigail ; Al-Hazaymeh, Amani ; Routes, John M. ; Verbsky, James ; Borish, Larry ; Lawrence, Monica G.</creatorcontrib><description>Purpose
Immunoglobulin E deficiency (IgED) (defined as IgE < 2 IU/mL) is enriched in patients with primary antibody deficiency (PAD). We hypothesized that selective IgED (sIgED) is a more sensitive predictor of the development of PAD than declining IgG, as IgE production typically requires two class switch recombination (CSR) events in contrast to IgG. Thus, the inability of patients with sIgED to mount an appropriate antibody response to a T-cell independent antigen or evidence of aberrant induction of ɛ germ line (ɛGL) or IgE heavy chain (IgEHC) transcripts in vitro would support the concept that sIgED is a biomarker for emerging PAD.
Methods
We compared pre- and post-polysaccharide vaccination titers in healthy patients with sIgED without a history of recurrent infections or autoimmunity (
n
= 20) and in healthy controls (HCs) (
n
= 17). Subsequently, we assessed in vitro induction of εGL and IgEHC transcripts in patients with sIgED and HC (
n
= 6) in response to IL-4 + CD40L stimulation.
Results
Thirty percent of patients with sIgED did not have a robust vaccine response compared to 0% of HCs (
p
= 0.017). Individuals with sIgED with an abnormal vaccine response demonstrated persistent germline mRNA expression in their B-cells at day 5, with lower levels of IgEHC, compared to both HCs and sIgED participants with a normal vaccine response.
Conclusion
Patients with sIgED are more likely to have abnormal antibody responses to a T cell–independent antigen and may have dysregulated CSR machinery. Following individuals with sIgED longitudinally may be beneficial in the early identification of PAD.</description><identifier>ISSN: 0271-9142</identifier><identifier>EISSN: 1573-2592</identifier><identifier>DOI: 10.1007/s10875-023-01501-y</identifier><identifier>PMID: 37169968</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Agammaglobulinemia ; Antibodies ; antibody formation ; Antibody response ; Antigens ; Autoimmunity ; biomarkers ; Biomedical and Life Sciences ; Biomedicine ; CD40L protein ; Class switching ; Gene expression ; germ cells ; Humans ; Immunoglobulin E ; Immunoglobulin G ; Immunologic Deficiency Syndromes - immunology ; Immunology ; Infectious Diseases ; Interleukin 4 ; Internal Medicine ; Lymphocytes B ; Lymphocytes T ; Medical Microbiology ; Original Article ; Polysaccharides ; Polysaccharides - immunology ; Primary Immunodeficiency Diseases - immunology ; Recombination ; T-lymphocytes ; vaccination ; Vaccines</subject><ispartof>Journal of clinical immunology, 2023-08, Vol.43 (6), p.1448-1454</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-7c67856acd2cb77e39599acf05db51a156a4edaf68e9f6bc2acf5455efdb72f03</citedby><cites>FETCH-LOGICAL-c408t-7c67856acd2cb77e39599acf05db51a156a4edaf68e9f6bc2acf5455efdb72f03</cites><orcidid>0000-0001-6450-3182</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10875-023-01501-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10875-023-01501-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37169968$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noonan, Emily</creatorcontrib><creatorcontrib>Straesser, Matthew D.</creatorcontrib><creatorcontrib>Makin, Thomas</creatorcontrib><creatorcontrib>Williams, Abigail</creatorcontrib><creatorcontrib>Al-Hazaymeh, Amani</creatorcontrib><creatorcontrib>Routes, John M.</creatorcontrib><creatorcontrib>Verbsky, James</creatorcontrib><creatorcontrib>Borish, Larry</creatorcontrib><creatorcontrib>Lawrence, Monica G.</creatorcontrib><title>Impaired Response to Polysaccharide Vaccine in Selective IgE Deficiency</title><title>Journal of clinical immunology</title><addtitle>J Clin Immunol</addtitle><addtitle>J Clin Immunol</addtitle><description>Purpose
Immunoglobulin E deficiency (IgED) (defined as IgE < 2 IU/mL) is enriched in patients with primary antibody deficiency (PAD). We hypothesized that selective IgED (sIgED) is a more sensitive predictor of the development of PAD than declining IgG, as IgE production typically requires two class switch recombination (CSR) events in contrast to IgG. Thus, the inability of patients with sIgED to mount an appropriate antibody response to a T-cell independent antigen or evidence of aberrant induction of ɛ germ line (ɛGL) or IgE heavy chain (IgEHC) transcripts in vitro would support the concept that sIgED is a biomarker for emerging PAD.
Methods
We compared pre- and post-polysaccharide vaccination titers in healthy patients with sIgED without a history of recurrent infections or autoimmunity (
n
= 20) and in healthy controls (HCs) (
n
= 17). Subsequently, we assessed in vitro induction of εGL and IgEHC transcripts in patients with sIgED and HC (
n
= 6) in response to IL-4 + CD40L stimulation.
Results
Thirty percent of patients with sIgED did not have a robust vaccine response compared to 0% of HCs (
p
= 0.017). Individuals with sIgED with an abnormal vaccine response demonstrated persistent germline mRNA expression in their B-cells at day 5, with lower levels of IgEHC, compared to both HCs and sIgED participants with a normal vaccine response.
Conclusion
Patients with sIgED are more likely to have abnormal antibody responses to a T cell–independent antigen and may have dysregulated CSR machinery. Following individuals with sIgED longitudinally may be beneficial in the early identification of PAD.</description><subject>Agammaglobulinemia</subject><subject>Antibodies</subject><subject>antibody formation</subject><subject>Antibody response</subject><subject>Antigens</subject><subject>Autoimmunity</subject><subject>biomarkers</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>CD40L protein</subject><subject>Class switching</subject><subject>Gene expression</subject><subject>germ cells</subject><subject>Humans</subject><subject>Immunoglobulin E</subject><subject>Immunoglobulin G</subject><subject>Immunologic Deficiency Syndromes - immunology</subject><subject>Immunology</subject><subject>Infectious Diseases</subject><subject>Interleukin 4</subject><subject>Internal Medicine</subject><subject>Lymphocytes B</subject><subject>Lymphocytes T</subject><subject>Medical Microbiology</subject><subject>Original Article</subject><subject>Polysaccharides</subject><subject>Polysaccharides - immunology</subject><subject>Primary Immunodeficiency Diseases - immunology</subject><subject>Recombination</subject><subject>T-lymphocytes</subject><subject>vaccination</subject><subject>Vaccines</subject><issn>0271-9142</issn><issn>1573-2592</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkVtLwzAYhoMobk7_gBdS8Mabag5Nk1zKnHMwUDzdhjT9OjO6diab0H9vdFPBC4VAAu_zvSF5EDom-JxgLC4CwVLwFFOWYsIxSbsd1CdcsJRyRXdRH1NBUkUy2kMHIcwxxiynfB_1mCC5Urnso_FksTTOQ5ncQ1i2TYBk1SZ3bd0FY-2L8a6E5DkeXQOJa5IHqMGu3Bskk9kouYLKWQeN7Q7RXmXqAEfbfYCerkePw5t0ejueDC-nqc2wXKXC5kLy3NiS2kIIYIorZWyFeVlwYkiMMihNlUtQVV5YGjOecQ5VWQhaYTZAZ5vepW9f1xBWeuGChbo2DbTroBnhcUlOs39RKgnjPFeERvT0Fzpv176JD4kUk1Jk8RcjRTeU9W0IHiq99G5hfKcJ1h9G9MaIjkb0pxHdxaGTbfW6WED5PfKlIAJsA4QYNTPwP3f_UfsO9QGWDw</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Noonan, Emily</creator><creator>Straesser, Matthew D.</creator><creator>Makin, Thomas</creator><creator>Williams, Abigail</creator><creator>Al-Hazaymeh, Amani</creator><creator>Routes, John M.</creator><creator>Verbsky, James</creator><creator>Borish, Larry</creator><creator>Lawrence, Monica G.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><orcidid>https://orcid.org/0000-0001-6450-3182</orcidid></search><sort><creationdate>20230801</creationdate><title>Impaired Response to Polysaccharide Vaccine in Selective IgE Deficiency</title><author>Noonan, Emily ; Straesser, Matthew D. ; Makin, Thomas ; Williams, Abigail ; Al-Hazaymeh, Amani ; Routes, John M. ; Verbsky, James ; Borish, Larry ; Lawrence, Monica G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-7c67856acd2cb77e39599acf05db51a156a4edaf68e9f6bc2acf5455efdb72f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Agammaglobulinemia</topic><topic>Antibodies</topic><topic>antibody formation</topic><topic>Antibody response</topic><topic>Antigens</topic><topic>Autoimmunity</topic><topic>biomarkers</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>CD40L protein</topic><topic>Class switching</topic><topic>Gene expression</topic><topic>germ cells</topic><topic>Humans</topic><topic>Immunoglobulin E</topic><topic>Immunoglobulin G</topic><topic>Immunologic Deficiency Syndromes - immunology</topic><topic>Immunology</topic><topic>Infectious Diseases</topic><topic>Interleukin 4</topic><topic>Internal Medicine</topic><topic>Lymphocytes B</topic><topic>Lymphocytes T</topic><topic>Medical Microbiology</topic><topic>Original Article</topic><topic>Polysaccharides</topic><topic>Polysaccharides - immunology</topic><topic>Primary Immunodeficiency Diseases - immunology</topic><topic>Recombination</topic><topic>T-lymphocytes</topic><topic>vaccination</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noonan, Emily</creatorcontrib><creatorcontrib>Straesser, Matthew D.</creatorcontrib><creatorcontrib>Makin, Thomas</creatorcontrib><creatorcontrib>Williams, Abigail</creatorcontrib><creatorcontrib>Al-Hazaymeh, Amani</creatorcontrib><creatorcontrib>Routes, John M.</creatorcontrib><creatorcontrib>Verbsky, James</creatorcontrib><creatorcontrib>Borish, Larry</creatorcontrib><creatorcontrib>Lawrence, Monica G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Journal of clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noonan, Emily</au><au>Straesser, Matthew D.</au><au>Makin, Thomas</au><au>Williams, Abigail</au><au>Al-Hazaymeh, Amani</au><au>Routes, John M.</au><au>Verbsky, James</au><au>Borish, Larry</au><au>Lawrence, Monica G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impaired Response to Polysaccharide Vaccine in Selective IgE Deficiency</atitle><jtitle>Journal of clinical immunology</jtitle><stitle>J Clin Immunol</stitle><addtitle>J Clin Immunol</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>43</volume><issue>6</issue><spage>1448</spage><epage>1454</epage><pages>1448-1454</pages><issn>0271-9142</issn><eissn>1573-2592</eissn><abstract>Purpose
Immunoglobulin E deficiency (IgED) (defined as IgE < 2 IU/mL) is enriched in patients with primary antibody deficiency (PAD). We hypothesized that selective IgED (sIgED) is a more sensitive predictor of the development of PAD than declining IgG, as IgE production typically requires two class switch recombination (CSR) events in contrast to IgG. Thus, the inability of patients with sIgED to mount an appropriate antibody response to a T-cell independent antigen or evidence of aberrant induction of ɛ germ line (ɛGL) or IgE heavy chain (IgEHC) transcripts in vitro would support the concept that sIgED is a biomarker for emerging PAD.
Methods
We compared pre- and post-polysaccharide vaccination titers in healthy patients with sIgED without a history of recurrent infections or autoimmunity (
n
= 20) and in healthy controls (HCs) (
n
= 17). Subsequently, we assessed in vitro induction of εGL and IgEHC transcripts in patients with sIgED and HC (
n
= 6) in response to IL-4 + CD40L stimulation.
Results
Thirty percent of patients with sIgED did not have a robust vaccine response compared to 0% of HCs (
p
= 0.017). Individuals with sIgED with an abnormal vaccine response demonstrated persistent germline mRNA expression in their B-cells at day 5, with lower levels of IgEHC, compared to both HCs and sIgED participants with a normal vaccine response.
Conclusion
Patients with sIgED are more likely to have abnormal antibody responses to a T cell–independent antigen and may have dysregulated CSR machinery. Following individuals with sIgED longitudinally may be beneficial in the early identification of PAD.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>37169968</pmid><doi>10.1007/s10875-023-01501-y</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-6450-3182</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0271-9142 |
| ispartof | Journal of clinical immunology, 2023-08, Vol.43 (6), p.1448-1454 |
| issn | 0271-9142 1573-2592 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2813556912 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Agammaglobulinemia Antibodies antibody formation Antibody response Antigens Autoimmunity biomarkers Biomedical and Life Sciences Biomedicine CD40L protein Class switching Gene expression germ cells Humans Immunoglobulin E Immunoglobulin G Immunologic Deficiency Syndromes - immunology Immunology Infectious Diseases Interleukin 4 Internal Medicine Lymphocytes B Lymphocytes T Medical Microbiology Original Article Polysaccharides Polysaccharides - immunology Primary Immunodeficiency Diseases - immunology Recombination T-lymphocytes vaccination Vaccines |
| title | Impaired Response to Polysaccharide Vaccine in Selective IgE Deficiency |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T00%3A51%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impaired%20Response%20to%20Polysaccharide%20Vaccine%20in%20Selective%20IgE%20Deficiency&rft.jtitle=Journal%20of%20clinical%20immunology&rft.au=Noonan,%20Emily&rft.date=2023-08-01&rft.volume=43&rft.issue=6&rft.spage=1448&rft.epage=1454&rft.pages=1448-1454&rft.issn=0271-9142&rft.eissn=1573-2592&rft_id=info:doi/10.1007/s10875-023-01501-y&rft_dat=%3Cproquest_cross%3E3153158524%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2838874914&rft_id=info:pmid/37169968&rfr_iscdi=true |